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Abstract
Background
While our institutional approach to esophageal resection for cancer has traditionally
favored a minimally invasive (MI) 3-hole, McKeown esophagectomy (MIE 3-hole), during
the last five years several factors have determined a shift in our practice with an increasing
number of minimally invasive Ivor Lewis (MIE IL) resections being performed. We
compared perioperative outcomes of the two procedures, hypothesizing that MIE IL would
be less morbid in the peri-operative setting compared to MIE 3-hole.
Methods
Our institution’s IRB-approved esophageal database was queried to identify all
patients who underwent totally MI esophagectomy (MIE IL vs. MIE 3-hole) from June 2011
to May 2016. Patient demographics, preoperative and peri-operative data, as well as
postoperative complications were compared between the two groups. Post-operative
complications were analyzed using the Clavien-Dindo classification system.
Results
There were 110 patients who underwent totally MI esophagectomy (MIE IL n=49
[45%], MIE 3-hole n=61 [55%]). The majority of patients were men (n=91, 83%) with a
median age of 62.5 (range: 31-83). Preoperative risk stratifiers such as ECOG score, ASA,
and Charlson Comorbidity Index were not significantly different between groups.
Anastomotic leak rate was 2.0% in the MIE IL group compared to 6.6% in the MIE 3-hole
group (p=0.379). The rate of serious (Clavien-Dindo 3, 4 or 5) post-operative complications
was significantly less in the MIE IL group (34.7 % vs. 59.0 %, p=0.013). Serious pulmonary
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complications were not significantly different (16.3 % vs. 26.2 %, p=0.251) between the
two groups.
Conclusions
In this cohort, totally MIE IL showed significantly less severe peri-operative
morbidity than MIE 3-hole, but similar rates of serious pulmonary complications and
anastomotic leaks. These findings confirm the safety of minimally invasive Ivor Lewis
esophagectomies for esophageal cancer when oncologically and clinically appropriate.
Minimally invasive McKeown esophagectomy remains a satisfactory and appropriate
option when clinically indicated.

Key Words: Esophageal cancer, Minimally Invasive Esophagectomy, Anastomotic Leak,
Ivor Lewis Esophagectomy, McKeown 3-hole Esophagectomy
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Introduction
The management of localized esophageal cancer consists of a multimodality
approach that includes surgeons, as well as medical and radiation oncologists. Early stage
disease can be treated with surgery alone, while locally advanced disease requires
neoadjuvant chemotherapy and radiation followed by surgical management [1]. While
esophagectomy, with or without neoadjuvant chemoradiotherapy, remains the cornerstone
of the treatment paradigm, it has been plagued by high rates of morbidity and mortality.
Perioperative morbidity rates continue to range from 26 to 41% [1, 2, 3].
Since the advent of minimally invasive techniques in the early 1990s [4, 5], there
have been improvements in short term outcomes while maintaining similar oncologic
efficacy as compared to traditional open surgery [6, 7, 8, 9].
For transthoracic minimally invasive esophagectomy (MIE), there exist two distinct
options: Ivor Lewis (MIE IL) and McKeown (MIE 3-hole) esophageal resections [10]. These
techniques have separately been shown to be efficacious in several high-volume centers
[11, 12, 13]. While the superiority of one procedure over the other continues to be matter
of debate, the MIE IL approach has been favored by an increasing number of surgeons [1].
The arguments used include: the perceived decrease in morbidity derived from an
anastomosis in the chest, increased recurrent laryngeal nerve injury and swallowing
dysfunction with cervical incisions, and a change in the epidemiology of esophageal cancer
with an increased number of adenocarcinomas of the distal esophagus and
gastroesophageal junction (GEJ) [12, 14]. However, there have been only a few attempts in
the literature to evaluate peri-operative outcomes in a head to head comparison of MIE IL
and MIE 3-hole [12, 15]. In the largest series by Luketich et al. [12] in 2012, there was a
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trend towards decreased major morbidity and mortality in the MIE IL group as compared
to MIE 3-hole. Two large randomized trials, the TIME trial [16, 17] and the MIRO trial [18]
looked at open versus MIE, separately using both MIE techniques, but did not compare MIE
IL to MIE 3-hole head to head.
In our institution, we have historically performed a McKeown esophagectomy but
have transitioned from McKeown to Ivor Lewis in recent years. In this analysis, we review
our experience with either intervention, comparing perioperative outcomes and
complication rates. We hypothesized that peri-operative morbidity in Ivor Lewis MIE
would be lower than McKeown MIE.

Materials and Methods
Inclusion and Exclusion Criteria
We identified patients from our Institutional Review Board-approved, prospectively
maintained database of patients who underwent esophagectomy for esophageal cancer at
our institution from June 2011 to May 2016 (IRB #12D.11). Patients were included if they
had undergone one of two techniques of totally minimally invasive esophagectomies: a
minimally invasive Ivor Lewis esophagectomy via a laparoscopic and thoracoscopic
approach or a minimally invasive McKeown esophagectomy - initially thoracoscopy,
followed by laparoscopy, and cervicotomy. Patients were excluded if they underwent a
hybrid surgical approach, defined as having had one of the components of the procedure
(abdominal or thoracic) completed in an open fashion. No transhiatal esophagectomies
were included in this analysis.

6
Oncologic Treatment Protocol
All patients were preoperatively staged using a variety of imaging techniques
including: contrast-enhanced CT scan of the chest/abdomen and pelvis, PET scan, and
endoscopic ultrasound. Following clinical staging, those patients with greater than a T2
lesion, as well as those with positive nodes, underwent neoadjuvant chemotherapy and
radiation consisting of induction radiation therapy with 4,500 cGy and either 5fluorouracil/cisplatin or 5-fluorouracil/carboplatin/paclitaxel chemotherapy with the
esophageal resection scheduled an average of 6 weeks after the completion of the
treatment. Those patients that were staged with under T2 disease, underwent primary
surgical resection.

Surgical Technique
Totally minimally invasive Ivor Lewis and McKeown esophagectomies were
performed as directed by surgeon preference and tumor location. This was accompanied
by a standard two-field lymphadenectomy, with removal of the left gastric and celiac nodes
in the abdomen, as well as the peri-esophageal and subcarinal nodes in the chest.
We have previously described our surgical technique for both MIE 3-hole and MIE IL
[7, 19]. In brief, during a MIE 3-hole, the procedure starts with the thoracoscopic
mobilization of the esophagus and lymphadenectomy through a right video-assisted
thoracoscopic surgery (VATS) approach, followed by laparoscopic gastric mobilization and
lymphadenectomy, as well as extracorporeal gastric conduit creation,
pyloromyotomy/pyloroplasty, and feeding jejunostomy placement in the supine position.
Finally, a linear stapled esophagogastrostomy is performed through a left cervical incision.
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The MIE IL is begun with the patient in the supine position, and through a
laparoscopic approach, key steps include: gastric mobilization, lymphadenectomy,
pyloromyotomy/pyloroplasty, gastric conduit creation, and feeding jejunostomy placement
[7]. The procedure is then completed through a right VATS approach, with esophageal
mobilization and lymphadenectomy being performed, followed by the creation of a
circularly stapled intrathoracic esophagogastric anastomosis.

Pathology
Patients included in this analysis underwent esophagectomy for adenocarcinoma or
squamous cell carcinoma of the esophagus, gastroesophageal junction, or gastric cardia.
The final pathologic staging was determined according to the 7th edition of the American
Joint Committee on Cancer staging system [20]. A complete pathologic response was
achieved when no tumor cells were identified. Completeness of the surgical resection
margin was defined as: no microscopic evidence of tumor at margin (R0), microscopic
evidence of tumor cells at the margin (R1), or macroscopic evidence of tumor at the
surgical margin (R2). All diagnoses were confirmed by two attending pathologists.

Surgical Complications and Perioperative variables
During chart review, data collected included age, sex, body mass index (BMI),
Eastern Cooperative Oncology Group (ECOG) performance status [21], American Society of
Anesthesiologists Physical Status Classification (ASA) [22], Charlson Comorbidity indices
(CCI) [23], initial histologic diagnosis and clinical staging, surgical technique, completeness
of resection, number of lymph nodes retrieved, estimated blood loss, and operating room
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time. ECOG performance status describes a patient’s level of functioning in terms of their
ability to care for themselves, daily activity, and physical ability [21]. It is scored from 0
(fully active) to 5 (dead). The ASA physical status classification describes operative risk as
it relates to the patient’s level of systemic disease. It is scored from ASA I (normal healthy
patient) to ASA VI (a declared brain dead patient, whose organs are for harvest) [22]. CCI
predicts one-year mortality for a patient with a variety of conditions. A score of 1,2,3 or 6 is
given to each of 22 different conditions with an age factor included to create an aggregate
score, with a higher score being associated with higher rates of mortality [23].
Furthermore, post-operative complications were graded using a modification of the
Clavien-Dindo (CD) scale [24]. The Clavien-Dindo classification is a scoring system based
on the interventions necessary to correct a post-operative complication. These range from
grade I (any complications that doesn’t need management, or simple medications such as
antiemetics), to grade 5 (death) [24].
Anastomotic leak was defined as purulent drainage including saliva or bile from the
neck drain or cervical incision, or infection of the neck incision and confirmation of leak by
a “grape juice test”, contrast swallow, or endoscopic confirmation [7]. Additional postoperative data included length of stay (LOS), and complications at 90 and 180 days postoperatively.

Statistical Analysis
Descriptive statistics were computed with frequencies, means, and medians, and
were stratified by the surgical approach. Quantitative analyses were performed using
Student’s t-tests and Fisher’s Exact Tests. Statistical significance was established at 0.05.
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Results
Demographics and Preoperative Factors
There were 110 patients who underwent either MIE IL or MIE 3-hole during the
time period. Of those patients, 49 (45%) underwent an MIE IL resection, while 61 (55%)
underwent a MIE 3-hole resection. Median age, sex, and BMI were not statistically
significant between the two groups. Of note, the majority of patients in both groups were
male (83.6% vs. 81.6%). Regarding preoperative diagnosis, the MIE IL group had
significantly higher stage tumors as shown in Table 1. The three measures for assessment
of preoperative morbidity are shown in Table 1, including ECOG, ASA, and CCI. Only ASA
scores were significantly different with the MIE 3-hole group being higher (2.92 vs. 2.73,
p=0.022). There was a trend towards more patients undergoing neoadjuvant treatment in
the MIE IL group (79.6%) as compared to the MIE 3-hole group (62.3%), but this was not
statistically significant (p=0.061).
Oncologic efficacy was evaluated in both minimally invasive procedures. The
percentage of R0 resections was 94% (MIE 3-hole) and 100%, (MIE IL) and were similar, as
were total lymph node harvested between groups. This is shown in Table 2. There was a
trend towards higher rates of positive lymph nodes harvested in the MIE IL group, but this
was not statistically significant. Neither estimated blood loss, nor operating room times
were significantly different between the two groups. Median length of hospital stay was
also similar between groups.

In-hospital Complications

10
Peri-operative complications were classified by specific complication category, and
graded according to Clavien-Dindo. As shown in Table 3, the anastomotic leak rate was
6.6% in the MIE 3-hole group, and 2.0% in the MIE IL group (p=0.379). Similarly, rates of
all pulmonary and cardiac complications were not statistically significant between groups
(p=0.310 and p=0.218 respectively). Rates of complications in all other physiologic
categories were not significantly different, including vocal cord paresis.
Rates of serious (CD grade  3) complications were analyzed between groups. The
rates of all serious complications was significantly higher in MIE 3-hole compared to MIE IL
(59.0 % vs. 34.7%, p=0.013). Serious anastomotic leaks, pulmonary and cardiac
complications, as well as infectious complications were not statistically different, as shown
in Table 4.

Follow-up
Mortality within 30 days was 1.6% (MIE 3-hole) vs. 6.1% (MIE IL), p= 0.322.
Readmission rates at 30 days were low in both groups, at 3.3% and 2.0%. Median follow-up
was 21.6 months (MIE 3-hole) and 9.0 months (MIE IL). The rates of serious complications
at 90 and 180 days were analyzed. Rates were not significantly different at either time
point. Short-term follow-up information is shown in Table 5. Of note, serious anastomotic
stricture rates were not different between groups at 180 days postoperatively. There were
no significant differences between the two groups in either overall survival (83.6% in MIE
3-hole vs. 79.6% MIE IL), or disease-free survival (73.8% vs. 63.2% respectively, p=0.300).

Discussion
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We have previously reported on the safety and oncologic efficacy of MIE in
esophageal cancer [7]. This initial experience was primarily with patients who had
undergone MIE 3-hole, but over the course of several years, we have modified our practice
to include MIE IL and MIE 3-hole. The trend from more MIE 3-hole to MIE IL has been the
result of the changing epidemiology of esophageal cancer, the increasing numbers of
gastroesophageal junction adenocarcinoma, and was stimulated by surgeon’s preference
within our group due to the perception of potentially fewer complications. A major reason
for the change in surgical technique stems from large cohort studies from high volume
centers showing potential improvement with MIE IL [12, 25]. The group led by Luketich et
al. described their transition from a MIE 3-hole to an MIE IL approach in large part due to
the morbidity associated with the cervical incision. They describe higher incidences of
anastomotic leak, anastomotic stricture, recurrent laryngeal nerve injury, and
pharyngoesophageal swallowing dysfunction following a MIE 3-hole approach. Their group
virtually eliminated recurrent laryngeal nerve injury, while limiting the length of the
gastric conduit required, and allowing for a more aggressive gastric resection margin by
switching to an MIE IL resection. That data has informed our group, and encouraged a
transition to minimally invasive Ivor Lewis esophagectomies for distal esophageal, and GEJ
tumors. This trend is reflected elsewhere in the literature with other surgeons having used
MIE IL resections for not only tumors of gastroesophageal junction, but also esophageal
tumors of the distal third of the esophagus [26]. In our institution, currently a MIE IL
resection is offered in all cases of esophageal cancer when clear margins can be obtained.
While the debate over the superiority of either approach (MIE IL vs MIE 3-hole) continues,
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we sought to review our current experience with these two techniques using a
standardized complications grading system [24].
In this report, the two cohorts that were compared appeared to be well matched
based on preoperative criteria. Regarding our ASA scores, the MIE 3-hole group has
significantly higher scores (2.92 vs. 2.73, p=0.022). While this could indicate that the MIE 3hole patients were sicker preoperatively, this scoring system is highly operator dependent,
and additionally, a 0.2 difference of mean score is likely not to be clinically significant. A
statistically significant difference was present in the preoperative stage between MIE IL
and 3-hole MIE. This may be the result of selection bias as patients with more advanced
disease could be allocated to MIE IL. Also, there was a trend, ultimately not statistically
significant, to more of the MIE IL patients having undergone neoadjuvant therapy which is
likely related to the higher preoperative stage.
Perioperative outcomes and oncologic efficacy, measured by completeness of
resection and number of LN harvested, were similar between the two groups. Furthermore,
the results show a significant difference in the totally minimally invasive Ivor Lewis
esophagectomy group having had significantly less severe complications (34.7%) than
minimally invasive McKeown esophagectomy (59.0%). Looking at a breakdown of all
complications between the two groups, there were similar rates of serious pulmonary
complications, cardiac complications, anastomotic leaks, and vocal cord paresis. Oncologic
efficacy, measured by completeness of resection and number of LN harvested, was similar
between the two groups. Interestingly, our patients who underwent MIE IL resection had
fewer serious complications while having a significantly higher preoperative clinical stage.
Notably, the incidence of GI related complications, including delayed gastric emptying and
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esophago-gastric anastomotic strictures among others, was not found to be statistically
significant in this cohort. In a previous analysis from our group looking at the number of
endoscopic interventions for gastrointestinal symptoms after MIE, we did identify a
marked difference in favor of MIE IL [27].
These data confirm the available evidence [12, 14] and provide results using a
standardized assessment with preoperatively clearly defined characteristics, and
postoperative severity of complications using a validated grading system (CD).
Luketich [11] et al. series of 222 patients who underwent MIE 3-hole showed
anastomotic leak rates of 11.7%, and rates of “major complications” of 32%. Our patient
series of MIE 3-hole compares favorably in terms of anastomotic leak rate and unfavorably
for overall major complications. In a separate series, the same authors reported a 4%
anastomotic leak rate with MIE IL, and a rate of “major morbidity” of 18% [12]. Our
anastomotic leak rate compares favorably, while our rates of major complications are
higher. In a very recent series, Straatman [28] et al showed that in 282 patients who
underwent MIE IL, there was a 15.2% anastomotic leak rate, 13.1% pulmonary
complication rate, and 4.3% cardiovascular complication rate. Our data shows higher rates
of cardio-pulmonary complications, but anastomotic leak rate superiority in a smaller
series. These results could be due to perioperative interventions (related to anesthesia,
patient positioning, length of surgical intervention, or postoperative pulmonary care) that
will require further analysis on our part. When comparing to the Straatman et al series, our
operative times of greater than 600 minutes differs greatly from their reported mean of
333 minutes [28]. Some of that difference may be due to differences in timing methodology
between institutions. At our institution, anesthesia time, as well as positioning and any
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pre-incision procedures are including in the operative length. Additionally, there are often
delays in repositioning between the abdominal and thoracic portions of the operation that
are being addressed.
Pulmonary complications in particular can provide significant morbidity following
esophagectomy. Regarding our data, we had rates of 26.5% (MIE IL) vs. 36.1% (MIE 3-hole)
in terms of overall complications including all Clavien-Dindo grades. With respect to
serious complications (CD grade greater than or equal to three), there were rates of 16.3%
(MIE IL) and 26.2% (MIE 3-hole). By comparison, in the TIME trial [16], the authors
reported all pulmonary complication rates of 12% in the MIE 3-hole group. Importantly,
these patients underwent the thoracoscopic portion of their procedure in the prone
position, which may positively impact their pulmonary complication rates. In the MIRO
trial [18], the authors report major pulmonary complication rates of 17.7% in their MIE IL
which is comparable to our data. With regards to one-year overall, and disease-free
survival, there was no significant difference between our two groups, but the follow-up is
very short. The aim of this study was focused on post-operative complications between the
two techniques, and survival will be addressed further in subsequent analyses.
The results reported here favor a trend towards performing a minimally invasive
Ivor Lewis esophagectomy for esophageal cancer when clinically and oncologically
appropriate.
This analysis obviously should be interpreted with caution due to limitations
intrinsic to the methodological design that need to be acknowledged. First, this is a
retrospective review of a relatively small sample size. There was no randomization to
surgical technique, and in general the choice of operation was based on surgeon
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preference. In recent years, patients with more distally located tumors were typically
offered an MIE IL resection. While this lack of randomization is somewhat limiting, our
patient cohorts appear to be well matched in terms of preoperative factors including ECOG
score and CCI, as well as age, sex, and BMI. This blunts some of the allocation bias
associated with a lack of randomization. Importantly, our MIE IL patients have significantly
higher preoperative clinical stages while still maintaining equal, and sometimes better
complication rates.
Second, data accrued from the MIE 3-hole group, while spanning all five years, is
more heavily weighted towards the beginning part of the study period. Even in that short
amount of time, there have been advances in perioperative anesthetic and critical care
management that may have impacted patient outcomes. These may sway complication
numbers in favor of MIE IL. Finally, our analysis comparing totally minimally invasive
options for esophagectomy exclude transhiatal MIE. This is not a procedure currently
performed at our institution, and conclusions regarding peri-operative complications of
MIE should be limited to comparisons between MIE IL and MIE 3-hole. The technical
challenges associated with a transhiatal approach have been well documented, and have
encouraged a transition to transthoracic approaches [29].
To our knowledge this is the first report to compare, in a standardized fashion, a
cohort of contemporary patients undergoing totally MIE with the two approaches of IL and
McKeown. We measured accepted preoperative characteristics, and utilized a validated
post-operative complications grading system. These data support minimally invasive Ivor
Lewis esophagectomy as a safer procedure for the treatment of esophageal cancer when
compared to minimally invasive McKeown esophagectomy. The results also confirm that
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minimally invasive McKeown esophagectomy, when clinically indicated, maintains a
satisfactory safety profile. Additionally, while pulmonary complication rates compared
favorably to some published reports on MIE, there is certainly an opportunity to improve
on the current data by considering additional perioperative pulmonary interventions.
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